Abstract

BackgroundWe aimed to analyze the clinicopathological features and outcomes of patients with gastric-type of HPV-independent endocervical adenocarcinoma (GAS HPVI ECA), and compare them with non-GAS HPVI ECA cases.MethodsThirty-eight GASs [including 17 minimal deviation adenocarcinoma (MDA), 21 non-MDA GAS] and 17 non-GAS HPVI ECAs were studied. Data of clinical features, pathological characteristics, treatment, and outcomes were evaluated.ResultsThe median age of patients with GAS and non-GAS HPVI ECA was 46 and 48 years, respectively (p = 0.93). Compared with non-GAS HPVI ECAs, GAS had more common complains of vaginal watery discharge (p = 0.04). GAS cases were also associated with higher clinical stage (p = 0.036), more common in deeper cervical stromal invasion (p = 0.002) and lymphoavascular invasion (p = 0.044). GAS was associated with worse median progression-free survival (PFS) (p = 0.02) and median overall survival (OS) (p = 0.03) over patients with non-GAS HPVI ECAs. MDA had similar clinical and pathological features and prognosis compared with non-MDA GAS. Of note, serum CA19–9 levels were significantly higher in GAS than that in non-GAS HPVI ECA cases.ConclusionsGAS cases were more likely to have high risk pathological factors and poorer PFS and OS compared with non-GAS HPVI ECAs. Serum CA19–9 may be helpful for diagnosis and screening in patients with GAS.

Highlights

  • We aimed to analyze the clinicopathological features and outcomes of patients with gastric-type of human papillomavirus (HPV)-independent endocervical adenocarcinoma (GAS HPVI Endocervical adenocarcinomas (ECAs)), and compare them with non-gastric type ECA (GAS) HPVI ECA cases

  • Our study indicated a similar result that Thinprep cytologic test (TCT) had a low positivity rate for HPVI ECAs (61.5% for GAS and 55.6% for non-GAS HPVI ECA)

  • We found that the serum CA19–9 level of patients with minimal deviation adenocarcinoma (MDA) GAS was significantly higher than that of patients with non-GAS HPVI ECA (161.0 U/ml vs 10.1 U/ml, p = 0.001)

Read more

Summary

Introduction

We aimed to analyze the clinicopathological features and outcomes of patients with gastric-type of HPV-independent endocervical adenocarcinoma (GAS HPVI ECA), and compare them with non-GAS HPVI ECA cases. Endocervical adenocarcinomas (ECAs) comprise up to 25% of all cervical cancers [1,2,3], and are frequently related to persistent infection of human papillomavirus (HPV) 16/18/45 [4]. HPV-associated ECAs [1, 3, 5, 6]. Unlike HPV-associated ECAs, non-HPV-associated ECAs are frequently located in the upper endocervix, resulting in missed detection or misdiagnosis [7, 8]. According to the 2020 World Health Organization (WHO) Classification of Female Genital Tumors [9], ECAs are subclassified into HPV-associated (HPVA) and HPV-independent (HPVI) groups.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call